Neurocrine falls on NBI-98854 tardive dyskinesia data

Neurocrine Biosciences Inc. (NASDAQ:NBIX) fell $4.96 (30%) to $11.74 on Tuesday after reporting late Monday that once-daily 50 mg oral NBI-98854 missed the primary endpoint in the Phase IIb Kinect Stu...